The Center for Biosimilars® recaps the top news for the week of April 8, 2019.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 8.
Number 5: Coherus BioSciences announced that its Udenyca sales for the past quarter are expected to be in the range of $36 million to $38 million.
Number 4: An advocacy group for patients with breast cancer in Canada recently published a series of recommendations after convening roundtable discussions with both patients and providers.
Number 3: During this week’s Congress of the Asia Pacific League of Associations for Rheumatology and Australian Rheumatology Association, multiple groups of researchers are reporting on the real-world use of biosimilars in rheumatology.
Number 2: Pfizer has launched its biosimilar trastuzumab, Trazimera, in Spain.
Number 1: Genentech has filed a new lawsuit over a proposed bevacizumab biosimilar.
Finally, last week, our e-newsletter asked whether you think drug makers will continue to invest in biosimilars in the long term.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Escaping the Void: All Things Biosimilars With Craig & G
August 5th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."